Fig. 5. Effects of EHMT2 inhibiton and/or Erlotinib on tumor growth in an EGFR-TKI-resistant xenograft model.
a Relative tumor volumes, b tumor weights, and c body weights were measured in PC9/ER xenografts treated with UNC0642, Erlotinib or the combination of UNC0642 and Erlotinib. d H3K9Me2, PTEN, p-AKT, and AKT expression levels were measured in PC9/ER xenograft tumor tissues. β-actin was used as a loading control. *P < 0.05, **P < 0.01, compared to control; #P < 0.05, combined treatment group compared to UNC0642 single treatment group